Revance Logo
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
ABOUTLEADERSHIPBOARDPARTNERSHIPS
SUSTAINABILITYMEDICAL EDUCATIONAL GRANTSINVESTIGATOR SPONSORED TRIALS
Company
INVESTOR RELATIONSPRESS RELEASESEVENTS + PRESENTATIONSFINANCIALS & FILINGSCORPORATE GOVERNANCE
STOCK INFORMATIONANALYST COVERAGEINVESTOR FAQSCONTACT US
Investors
OPPORTUNITIESCULTUREBENEFITS
Careers
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
Facebook logoInstagram logoTwitter logoLinkedIn logo
1222 Demonbreun St
20th Floor
Nashville, TN 37203
+1 (510) 742-3400
LoginContact Revance
Back
November 4, 2015
Revance Therapeutics Announces Pricing of Public Offering of Common Stock
November 2, 2015
Revance Therapeutics Announces Proposed Public Offering of Common Stock
October 29, 2015
Revance Reports Positive 6-Month Duration in BELMONT Study
September 29, 2015
Revance Therapeutics Initiates Phase 2 Clinical Study of Its Unique Botulinum Toxin Type A for Injection to Treat Cervical Dystonia
September 28, 2015
Revance Therapeutics Initiates Phase 3 Clinical Trial of Botulinum Toxin Type A Topical Gel to Treat Lateral Canthal Lines
September 9, 2015
Revance Therapeutics Initiates Phase 2 Clinical Trial of Botulinum Toxin Type A Topical Gel to Treat Axillary Hyperhidrosis
August 6, 2015
Revance Therapeutics Releases Second Quarter 2015 Results
July 23, 2015
Revance Therapeutics to Release Second Quarter 2015 Financial Results Thursday, August 6, 2015
July 2, 2015
Revance Therapeutics Announces Change in Role of Jacob Waugh, M.D.
June 3, 2015
Revance Therapeutics to Initiate Two Key Trials for RT001, Its Topical Botulinum Toxin Type A Investigational Drug Product Candidate
Displaying 241 - 250 of 296